P80: a tumor-related protein found in many lymphomas of mice by unknown
P80:  A  TUMOR-RELATED  PROTEIN  FOUND 
IN  MANY  LYMPHOMAS  OF  MICE* 
BY DAVID J. GRUNWALD,:I: KENNETH MILLER, AND REX RISSER§ 
From the McArdle Laboratory  for Cancer Research, University of Wisconsin, Madison, Wisconsin 53706 
Biochemical  identification  of tumor-specific  antigens  has,  with  rare  exceptions, 
proved  to  be  a  difficult  goal.  Even  the  thymus  leukemia  (WE) 1 antigen,  which  is 
clearly tumor specific in some strains of mice, has been found as a normal constitutent 
of thymus cells in other strains of mice  (1,  2).  Tumor-specific antigens encoded  by 
transforming  viruses  have  proved  far  more  amenable  to  analysis  (3),  and  genetic 
experiments have demonstrated  (4,  5)  that  these proteins play essential  roles in  in 
vitro transformation. These proteins, which include  the avian sarcoma virus pp60  ~c 
(3), the Abelson murine leukemia virus (A-MuLV) gag-fusion  proteins p120 or p160 
(6-8), and the feline sarcoma virus protein  (9), are usually found phosphorylated in 
vivo,  and  immunoprecipitates  of  these  proteins  catalyze  the  phosphorylation  of 
tyrosine residues on other proteins (10-13). Aside from these virally encoded proteins, 
a phosphoprotein(s) of-53,000 mol wt, encoded by a cellular gene(s), has been found 
in  elevated  amounts  in  a  wide  variety  of tumors  and  transformed  ceils  (14-16). 
Although  expression of both viral and cellular phosphoproteins has been correlated 
with  transformation,  the  precise  molecular rate of such  proteins  in  transformation 
remains to be elucidated. 
It  has  usually  been  found  that,  when  ceils  transformed  by  retroviruses  cease 
expression of the virally encoded transforming protein, the cells also revert to normal 
morphology and growth properties. Thus, morphological revertants of cells, initially 
transformed by A-MuLV  strains  encoding  the  p120  (17)  and  p160  (18)  gag-fusion 
proteins,  no  longer synthesized  these  proteins.  Recently,  we observed an  apparent 
exception to this generalization. At least one A-MuLV lymphoma, cloned repeatedly 
in vitro and found to express the A-MuLV gag-fusion protein p160, gives rise to tumor 
clones that no longer express the A-MuLV gag-fusion  protein after growth in vivo in 
genetically distinguishable host mice. These novel cells are clearly of donor cell origin 
and are highly malignant in adult syngeneic mice (19). Tumor regressor sera prepared 
to such p 160-negative tumors, as well as tumor regressor sera prepared to several other 
mouse  lymphomas,  immunoprecipitate  three  previously  unidentified  proteins,  the 
properties of which we report here. 
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Materials  and  Methods 
Animals.  Mice were bred in our colony at the McArdle Laboratory or purchased from The 
Jackson Laboratory,  Bar Harbor,  ME. 
Tumor Cells.  The transplantable tumors EL4, ERLD, EdG2, RLc~I, Meth A, ASLI, RADA- 
1, AKSL2, and K36 were obtained  from Dr. E. Stockert and Dr.  L. J. Old, Memorial Sloan- 
Kettering Cancer  Center,  New York,  the origin  and  maintenance  of these  tumors  has  been 
described  (20).  RBL-5, a  transplantable  B6  Rauscher MuLV lymphoma, was obtained  from 
Dr. F. Bach, University of Minnesota, Minneapolis, MN, and was maintained by weekly ascites 
transfer of 107 cells in B6 mice. BALENTL 9, a transplantable  BALB/c lymphoma induced by 
ethylnitrosourea  (21),  was obtained from Dr. M.  Potter, Laboratory of Cell Biology, National 
Cancer Institute, National Institutes of Health, Bethesda,  MD, and was maintained by ascites 
transfer of 107 cells in pristane-primed BALB/c mice. 
The derivation of A-MuLV lymphoma lines that  differ in their expression of the A-MuLV 
gag-fusion protein  has been described recently  (19).  The lymphomas B6T1, B6T4, and  B6T6 
were  induced  in  neonatal  B6  mice  by  infection  with  the  NIH  strain  of  A-MuLV  and 
transplanted  intraperitoneally in semi-syngeneic irradiated hosts. Tumors transferred  for a  few 
transplants  (0-5)  are designated early (E), and tumors transferred  for several transplants  (12- 
45) are designated late (L). The clonal lines E2 and E3 were derived from early B6T1 cells after 
adaptation  to tissue culture. The cells were cloned once in methylcellulose suspension, and E2 
cells were cloned a second time by terminal dilution at 0.1  cells/well. The cloning efficiency in 
the second cloning experiment was 40%. E2 cells were then used to initiate a new tumor line by 
transplanting  10  v cells into irradiated  (BALB/c ×  B6)F1 mice. After five in vivo transplants, 
the cells, now called E2Fi, were placed back into culture and examined for expression of H-2 
antigens  and  glucose phosphate  isomerase  (Gpi-1)  isoenzyme markers,  which  differ between 
donor  (B6)  and  host  (BALB/c  ×  B6)2  animals.  E2F1 cells were  found  to be of B6  parental 
origin (19).  A  similar protocol was used to derive the line FllA from E3 cells. FI1A cells were 
recovered from transplanted  E3 cells after seven in vivo passages and were shown to be of B6 
origin (19). 
Cell Cultures.  The origins of cell lines NIH3T3,  NRK,  RAT-I, the A-MuLV nonproducer 
cells ANN-1 and AbNRK, the SFFV nonproducer cells SFFV-NIH and SFFV-NRK, a  SV40- 
transformed  rat  embryo  fibroblast  line  SVRE  17,  and  an  A-MuLV-transformed  BALB/c 
lymphoid line  18-4  have been  described elsewhere  (22  25).  Cell cultures  were also  prepared 
from  14-16-d BALB/c and B6 fetuses. 
Mixed Lymphocyte  Cultures.  B6  spleen  cells were  incubated  either  alone  or with  an  equal 
number of mitomycin C-treated BALB/c spleen cells in Mishell-Dutton medium supplemented 
with 2% fetal bovine serum (FBS) and 5 ×  10 -5 M  2-mercaptoethanol. After 70, 96, and  120 h, 
six replicate cultures of stimulated and nonstimulated spleen cells were each incubated at 37 °C 
for  6  h  with  1 /~Ci  of [methyl-3H]thymidine  (80  Ci/mmol).  Uptake  of [3H]thymidine  was 
maximum at 96 h, at which time stimulated cells incorporated  16-fold more thymidine (135,790 
+  5305 cpm) than did unstimulated cells (8,488 +  1865  cpm). 
Antisera  and  Cytotoxicity  Tests.  Goat  antisera  directed  against  Rauscher  murine  leukemia 
virus structural  proteins  p15,  pr65,  and  gpT0 were obtained  from  R.  Wilsnack  through  the 
offices of the Special Virus Cancer Program,  NCI, NIH. The antisera  B6 anti-B6T1,  (C3H  X 
B6)Fx anti-B6T1, B6 anti-B6Mo3, and BALB/c anti-EL4 were prepared as described  (22,  26). 
The antiserum B6 anti-A-MuLV was prepared according to the method described for B6 anti- 
FV (23).  Monoclonal Thy- 1 antibody was purchased from New England Nuclear, Boston, MA, 
and used in direct cytotoxicity tests  (22)  at dilutions of 10 .3 to  10 -5 or in absorption  tests at a 
dilution of 10  .2 . 
Radioisotopic  Labeling  of Cells.  Subconfluent  monolayers  of fibroblasts  or  10 v nonadherent 
cells were incubated  at  37°C  for 2-4  h  with  200-400  #Ci of [SSS]methionine  (700-1,300  Ci/ 
mmol) in RPMI  1640 medium lacking methionine and supplemented with  10% dialyzed FBS. 
Cells were also  labeled  for 2.5  h  with  500/zCi  [a2p]orthophosphate  in phosphate-free  RPMI 
1640  medium  supplemented  with  10%  dialyzed  FBS.  For  experiments  with  tritiated  sugar 
precursors, cells were incubated at 37°C for 2 h with 250/zCi of [aH]glucosamine (38 Ci/mmol) 
or  [aH]mannose  (7.2  Ci/mmol)  in  glucose-free minimum  essential  medium.  Incoporation  of 
radiolabel was terminated by the addition of 0.25 volumes of 5)< lysis buffer (0.05 M  NaHPO4, DAVID J.  GRUNWALD,  KENNETH MILLER, AND  REX RISSER  1197 
pH 7.2, 4.5% NaCI, 5% Triton X-100, 2.5% sodium deoxycholate, 0.5% sodium dodecyl sulfate 
(SDS), and 5% Trasylol (protease inhibitor)).  Cell extracts were incubated with nonimmune 
mouse serum for 1 h, and then, after the addition of formalin-fixed Staphylococcus aureus bacteria, 
Cowan  strain  I  (27),  the  lysates were  centrifuged  at  120,000  g  for 90  min.  The  resulting 
supernatant was used in subsequent immunoprecipitation reactions as described. 
Cells in phosphate-buffered saline were radioiodinated by the lactoperoxidase method (28), 
washed in  10 mM KI-phosphate-buffered saline, and resuspended in 0.8 ml hypotonic buffer 
(10 mM Tris-HC1, pH 7.4, 10 mM NaC1,  1.5 M  MgCIz). Lysates were then prepared as above. 
Immunoprecipitation and SDS-Polyac~ylamide Gel Analysis.  Cell extracts (1-20 ×  10  ° cpm) were 
incubated with 1-10 ~1 of goat or mouse antiserum at 4°C for at least  1 h. Immune complexes 
were collected by the addition of 200 #1 of a  10% vol/vol solution of the S. aureus bacteria in 
RIPA buffer  (3)  followed by centrifugation.  After four washes with  RIPA buffer,  immune 
complexes were solubilized by heating at  100°C for 5 min in sample buffer (26). 
Immunoprecipitated proteins were electrophoresed through 10% SDS-polyacrylamide slab 
gels as described (29). After fixation and staining, gels that contained either 3SS- or 3H-labeled 
proteins were prepared  for fluorography (30),  dried,  and exposed to X-omat R  Kodak film 
32  125  (Eastman Kodak Co., Rochester, NY). Gels containing  P- or  I-labeled proteins were dried 
and  exposed  to X-omat  R  Kodak  film  in  the  presence  of an  intensifying  screen.  All  gels 
contained the standard marker proteins RNA polymerase subunits (160K, 150K, 90K, 36.5K), 
fl-galactosidase (116K), phosphorylase A (96K), bovine serum albumin (68K), and ovalbumin 
(43K). 
Tryptic Peptide Analysis.  Immunoprecipitated proteins were resolved on preparative cylin- 
drical gels. Proteins were eluted from appropriate gel slices and trypsinized according to the 
method of Kew et al. (31). Peptides were applied to a column of Technicon Chromobeads type 
P  cation  exchange  resin,  and  the  chromatogram was  developed  with  a  linear  gradient  of 
pyridine acetate, increasing in pH and concentration (0.2 M, pH 3.1, to 2 M, pH 5.0) for the 
first  200 fractions. The column was then washed with 2 M  pyridine acetate  (pH 5.0) for the 
final 50 fractions (31). 
Results 
Identification  of Novel  Proteins  in  A-MuLV  Lymphomas  That  Cease Expression  of the 
A-MuL V Gag-Fusion Protein.  We recently observed that continued in vivo propagation 
of some  A-MuLV  lymphomas  results  in  the  appearance  of tumor  cells  that  are 
different  from  most  A-MuLV  lymphoma  cells  in  the  expression  of the  A-MuLV- 
encoded gag-fusion  protein  (19). Tumor cells recovered after several in vivo passages 
(p 12-p45)  no longer synthesized  detectable  amounts  of the  A-MuLV-encoded gag- 
fusion protein p 160, although this protein was readily detectable in earlier transplants 
(0-5) of the same tumors (32). 
To detect other tumor-specific proteins synthesized by these unusual p 160-negative 
cells,  B6  mice  were  immunized  with  tumor  cells  from  late  transplant  generations 
(p15-p45)  of the A-MuLV-induced lymphoma,  B6T1,  referred  to as B6TI(L)  cells. 
Extracts of B6T 1 (L) cells, which had been metabolically labeled with [35S]methionine, 
were mixed with tumor regressor serum and the immunoprecipitated proteins resolved 
by electrophoresis through SDS-polyacrylamide gels and visualized by fluorography. 
Six protein species of molecular mass  115K, 85K, 80K, 65K, 32K, and  15K mol wt 
were observed in this experiment  (Fig.  1, lane b). The two proteins of 85K and  15K 
comigrated with the env gene products pr85 e"° and p 15E (Fig.  1, lane c). The proteins 
of 85K, 65K, and 15K bear only viral antigenic determinants because the precipitation 
of these proteins was blocked when unlabeled disrupted M-MuLV virions were added 
to the immunoprecipitation  reaction  (Fig.  1, lane a).  Because the proteins  of 115K, 
80K,  and  32K  were  precipitated  in  reactions  containing  exogenous  unlabeled  M- 
MuLV,  these  proteins  must  bear  antigenic  determinants  not  shared  by  M-MuLV 1198  P80:  A TUMOR-RELATED  PROTEIN  OF MOUSE  LYMPHOMAS 
Fro.  1.  Recognition of nonviral proteins by regressor serum prepared against the B6TI(L)  tumor. 
ssS-labeled extracts of B6TI(L)  cells were prepared and analyzed  as in Materials and Methods. 
Proteins were immunoprecipitated with B6 anti-B6T 1  (L) antiserum  (lane B) with B6 anti-B6T1 (L) 
antiserum that had been preincubated with disrupted M-MuLV virions (lane A) or with goat anti- 
gp70 serum (lane C). 
structural proteins. 
To determine whether expression of p 115, p80, and p32 was also observed in clonal 
lines  that  no  longer  expressed  the  A-MuLV  fusion  protein  p160,  the  following 
experiment  was  performed.  E2  cells  derived  by  repeated  cloning  (40%  cloning 
efficiency) of early passage B6T1  tumor cells were used to initiate a  new  tumor line 
in genetically distinguishable host mice. After five in vivo transplants, the tumor cells, 
termed E2F1, were placed back into culture and  checked for the presence of H-2 or 
Gpi-1  markers  to  determine  whether  the  cells  were  derived  from  the  donor  cell 
population or from the host.  E2F1 cells expressed only the H-2  b antigens and  Gpi-1 b 
isoenzyme characteristic of the donor  (19).  The  initial E2  and  derivative E2Fx cells 
were then radiolabeled and examined for synthesis of the A-MuLV gag-fusion  protein 
p160  using anti-gag p15  serum  or the p115,  p80,  p32  molecules detected with  anti- 
p80  tumor regressor serum  (Fig. 2).  Under  these conditions, p160  and  pr65  gag were 
readily  detected  in  E2  cells  (Fig.  2,  lane  b),  whereas  no  protein  was  specifically DAVID J.  GRUNWALD, KENNETH  MILLER,  AND REX  RISSER  1199 
FIc. 2.  Expression  of p80 and the A-MuLV protein p160 in clonal lines. Lysates of E2 (a-c) and 
E2F1 (d-f) cells (see text), radiolabeled with [aSS]methionine,  were immunoprecipitated with normal 
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F~o.  3.  Expression  of the Thy-1 antigen by p80- and pS0  + A-MuLV lymphoma cells. Monoclonal 
Thy-l.2 antibody was used in (A) direct cytotoxic tests with thymocytes from B6 mice (--), E3 cells 
(O), and FI1A cells (A) or (B) was absorbed with B6 thymocytes (--), E3 cells (O) or FllA (A) and 
tested on B6 thymocyte target cells. The cytotoxic activity of unabsorbed serum used in absorption 
tests is indicated (V), as is lysis  in the presence of complement alone (m). 
immunoprecipitated from E2 cells with anti-p80 serum  (Fig. 2, lane c).  Conversely, 
pr65  gag but not p160 was detected in E2F1 cells (Fig. 2, lane e), and p80 was readily 
detected in these cells (Fig.  2, lane f).  Moreover, nucleic acid hybridization experi- 
ments indicated that most, if not all, of the A-MuLV proviral genome was lost from 
E2F1 cells (19). A similar result was observed when E3 cells were compared with F11A 
cells, a  line derived from E3 after seven in vivo passages. Thus, it is apparent that the 
A-MuLV-encoded protein p160 and the p80 protein, identified with tumor regressor 
sera, bear non-cross-reactive antigenic determinants. 
An additional feature that distinguished p 160-positive and p 160-negative cells was 
the expression of the Thy-1 differentiation antigen. When the p 160-positive A-MuLV 
lines E2  and  E3  were  examined in  direct  cytotoxic  tests  with  monoclonal Thy-1 
antibody, the cells were refractory to lysis, whereas FllA or E2F1 cells, derived from 
E3  or  E2  cells,  respectively, showed  95%  lysis  (Fig.  3 A  and  data  not  shown).  To 
confirm the cell surface phenotype of these lines, absorption analysis was performed. 1200  PS0: A TUMOR-RELATED PROTEIN OF MOUSE LYMPHOMAS 
The results of that experiment  demonstrate that  neither E3  nor E2 cells absorbed 
cytotoxic  activity,  whereas  FllA  cells,  E2F1  cells,  and  thymocytes  absorbed  all 
cytotoxic antibody (Fig.  3 B and data not shown). Therefore, we conclude that E2 
and E3 cells have the phenotype p160*, p80-, Thy-1- and that FllA and E2F1 cells 
have the phenotype p160-, p80 +, Thy-l*. 
Comparison of  p80 and the A-MuL V-encoded Protein p 120.  Serologically, the A-MuLV- 
encoded gag-fusion protein appeared distinct from p80  (Fig.  2). To confirm the lack 
of relatedness of p80 to A-MuLV-encoded gag-fusion proteins, the tryptic peptides of 
p80  were  compared  with  those of the  A-MuLV-encoded protein  p120  (P120  was 
selected because larger amounts of it could be recovered and because p 120 and p 160 
share 15 tryptic peptides)  (19). After immunoprecipitation with anti-pr65 antiserum 
from 35S-labeled  lysates of 18-4 cells, the gag-fusion product, p 120, was isolated from 
preparative SDS-polyacrylamide gels. Similarly, p80 was purified by gel electropho- 
resis  of immunoprecipitates  from  B6TI(L)  cells.  The  two  purified  proteins  were 
trypsinized in parallel, and their peptides were applied to a sulfonated ion exchange 
column and eluted with a linear gradient of pyridine acetate (31). The profile of the 
methionine-containing peptides of p120  (Fig.  4, panel C)  is quite different from the 
pattern  of the  p80  peptides  (panel  B).  Comparison  of the  methionine-containing 
peptides of p160 (19) and p80 also demonstrated very different patterns. Thus, from 
both  serological  and  biochemical  analyses,  there  appears  little,  if any,  homology 
between p80 and the gag-fusion products of A-MuLV. 
The relationship of the three nonviral proteins, p80, p32, and p 115, precipitated 
from the B6TI(L)  cells,  was examined. Under nonreducing denaturing conditions, 
p115  did not appear to be complexed with other proteins  (data not shown). Pulse- 
chase analyses indicated that, whereas p115 was not a  precursor polyprotein for the 
smaller proteins, p32 might represent a stable proteolytic product derived from p80 
(data not shown). The relatedness of p80 and p32 was confirmed by comparison of 
their  methionine-containing tryptic peptides.  Lysates of a~S-labeled  B6TI(L)  cells 
were  prepared  and  immunoprecipitated  with  anti-p80  antiserum.  The  immune 
complexes were collected and resolved in preparative SDS-polyacrylamide gels from 
which p32 and p80 were purified. After trypsinization, p32 (Fig. 4, panel A) and p80 
(panel B) were chromatographed in parallel. The two proteins share several peptides, 
five of which are noted in  Fig.  4.  Because of the difficulty of obtaining sufficient 
material of p115, a similar comparison with this protein has not been performed. At 
present the relationship, if any, between p115 and p80 has not been elucidated. 
PSO Is a Nonglycosylated Phosphoprotein.  B6T 1  (L) cells were incubated in phosphate- 
free medium supplemented with [aZp]orthophosphate. Extracts of these cells were then 
immunoprecipitated with  either  anti-p80  serum  (Fig.  5,  lane  a)  or  goat  anti-pl2 
serum  (lane  b),  and  the  reactive  phosphorylated  proteins  were  resolved  by  gel 
electrophoresis and visualized by autoradiography. Under these conditions of meta- 
bolic labeling, both p80 and pr65 gag appear phosphorylated in these cells;  however, 
p32 does not appear to be. 
Although antibodies against p80 are frequently produced after hyperimmunization 
with  many tumor  lines,  we  have  no  evidence  that  p80  was  expressed  at  the  cell 
surface. Although the viral glycoprotein (gp70)  present at the surface of B6T 1  (L) cells 
was readily iodinated by the lactoperoxidase method (Fig. 5, lane d), a technique that 
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Fie. 4.  Comparison of the methionine-containing tryptic peptides of p32, p80, and p120. After 
immunoprecipitation, the proteins were purified by elution from preparative SDS-polyacrylamide 
gels. P32 (A), pS0 (B), and p120 (C) were trypsinized in parallel, and their peptides were resolved 
by chromatography. Labeled peaks represent peptides shared by pS0 and p32. 
radioactive  material  was  precipitated  by either  nonimmune  B6 or anti-p80  serum 
(Fig.  5, lanes c  and e).  Similarly,  the M-MuLV  env gene products pr85 env and gp70 
could be metabolically labeled in B6T1 (L) cells with [ZH]glucosamine (Fig. 5, lane g) 
or [~H]mannose (lane i), but p80 was not labeled with these sugar precursors  (Fig. 5, 
lanes  f  and  h).  A  further  indication  that  p80  was  not  glycosylated  came  from 
experiments in which B6TI(L) cells were incubated with the antibiotic tunicamycin, 
which inhibits glycosylation. Increasing concentrations of tunicamycin in the medium 
had a  marked  effect on the apparent  mobility of the env gene products of B6TI(L) 
cells but did not alter the rate of synthesis nor the mobility of pS0 (data not shown). 
PSO Is Synthesized by Many T  Cell Lymphornas of Mice.  To  determine  whether  the 
expression of p80 was a  property limited to A-MuLV-induced tumors that no longer 
expressed  the gag-fusion  protein, several murine  tumors were examined  for synthesis 
of this protein. Each tumor line was metabolically labeled with [~S]methionine, lysed, 
and incubated  with either  nonimmune mouse or anti-p80  serum  in  the presence of 
disrupted  M-MuLV  virions.  The results of such direct  immunoprecipitation  experi- 1202  P80:  A TUMOR-RELATED  PROTEIN  OF MOUSE  LYMPHOMAS 
Fro.  5.  Physical characterization  of p80. B6TI(L)  cells were either labeled with [a2P]orthophos- 
phate (lanes a and b), radioiodinated by the lactoperoxidase  method  (c-e), or labeled with  the 
tritiated sugar precursors, [3H]glucosamine (f and g) and [3H]mannose (h and i). Extracts of these 
cells were immunoprecipitated  as in Materials and Methods with anti-p80 antiserum in the presence 
of M-MuLV virions (a, e, f, and h), goat anti-pr65 serum  (b), nonimmune  mouse serum  (c), and 
goat anti-gp70 serum (d, g, and i). 
ments (Fig. 6, Table I) indicate that P80, p115,  and p32 were observed in many, but 
not all, T  cell lymphomas of B6, BALB/c, and A/J  mice. This group of p80-positive 
tumors included Thy-1-positive transplanted lymphomas that arose spontaneously or 
were  induced  by  the  Friend,  Moloney,  or  Rauscher  MuLV  strains  by  a  chemical 
carcinogen, dimethylbenzanthracene, or by radiation. Several B6 A-MuLV-induced 
lymphomas  that  had  ceased  expression  of their  gag-fusion  proteins  upon  in  vivo 
propagation (32) also synthesized p80. 
Among those tumors in which p80 was not detected, were four A-MuLV-induced 
lymphomas that synthesized A-MuLV gag-fusion  proteins. Several other lymphomas 
of B6, BALB/c, A/J, and AKR  mice, some of which expressed the Thy- 1 antigen, as 
well  as  a  transplanted  BALB/c  sarcoma,  did not  synthesize detectable amounts  of 
p80. 
The  80,000  mol  wt  species  detected  in  three  different  tumors  were  compared 
according to the method of Cleveland et al. (34). Extracts of B6T 1  (L) cells, EL4 cells, 
a  chemically-induced B6 tumor, and RLdl  cells, a  radiation-induced BALB/c tumor, 
were immunoprecipitated with anti-p80 antiserum. The pS0 molecules were partially 
purified by gel electrophoresis and then enzymatically digested with varying amounts 
of S.  aureus V8  protease  (Fig.  7).  The  pattern  of the  proteolytic products  generated 
from  the p80  proteins of EL4  and  RLdl  tumor cells was similar to  that  of the p80 
protein from B6T1 (L) cells. 
The  distribution of murine  tumors  with  p80  suggested  that  this  protein  did  not 
serve as a  generalized marker of transformed cells. Among in vitro cultured cells, p80 
has only been  detected in cell lines derived from p80-positive tumor cells (Table I). 
NIH3T3  and  NRK  cells,  either  uninfected  or  harboring  the  replication  defective DAVID J.  GRUNWALD, KENNETH  MILLER, AND REX  RISSER  1203 
Fio. 6.  Several  murine lymphomas synthesize pS0. ~S-labeled extracts of tumor cells were im- 
munoprecipitated and analyzed in SDS-polyacrylamide  gels. Proteins were immunoprecipitated 
with nonimmune mouse serum (n) or anti-p80 antiserum (or) in the presence  of M-MuLV virions. 
The marker lane represents known MuLV proteins synthesized by B6T6 tumor ceils and immuno- 
precipitated with goat antiserum prepared against disrupted M-MuLV virions. 
genomes of A-MuLV or SFFV, did not synthesize detectable levels of p80  (data not 
shown). In competition experiments for the 35S-labeled p80 of B6TI(L) cells, nonra- 
dioactive lysates of these cells also failed to inhibit precipitation of p80. Similarly, p80 
was  not  detected  in  RAT-1  cells,  SV40  transformed  rat  embryo  fibroblasts,  nor 
secondary cultures of mouse embryo fibroblasts from B6 and BALB/c mice (data not 
shown). The A-MuLV-transformed lymphoid line  18-4 that synthesized the p 120 gag- 
fusion protein also did not synthesize p80  (data not shown). 
Syngeneic  and  semisyngeneic hyperimmunization  with  B6TI(L)  cells  invariably 
led to the production of p80-reactive antibodies (Table II). However, syngeneic tumor 
regressor antisera that  were prepared against  pl60-positive E2  cells and  recognized 
the  A-MuLV-specific  portion  of  the  virally  encoded  gag-fusion  protein,  did  not 
immunoprecipitate p80  from B6TI(L) cells.  Antisera prepared by syngeneic immu- 
nization with M-MuLV tumor cells and by allogeneic immunization with EL4 cells 
were capable of immunoprecipitating p80 from B6T 1  (L) cells. Thus, p80 appears to 
be an immunogenic protein expressed by several T  cell lymphomas of different strains 
of mice. 
P80 Is Not  Detectable  in  Normal Lymphoid  Tissue.  The  presence of p80  in  normal 
lymphoid tissue was examined by metabolic labeling of normal cells and by compe- 
tition experiments with lysates of nonradioactive lymphoid cells. Cells from the bone 1204  P80:  A TUMOR-RELATED  PROTEIN  OF MOUSE  LYMPHOMAS 
TABLE  [ 
Synthesis of  pSO in Mouse Tumors and Cell Lines 
Tumor line  Strain  Inducing Agent  Thy- 1" 
pS0-positive tumors 
FllA (p160-)  B6  A-MuLV  + 
E2F1 (p 160-)  B6  A-MuLV  + 
B6T1 (L) (p160-)  B6  A-MuLV  + 
B6T4(L) (p160-)  B6  A-MuLV  + 
B6T6(L) (p 160-)  B6  A-MuLV  + 
B6FRd2  B6  Friend MuLV  + 
B6Mo3  B6  M-MuLV  + 
RBL-5  B6  Rauscher MuLV  + 
EL4  B6  Dimet hylbenzanthracene  + 
ERLD  B6  Radiation  +~: 
RLd 1  BALB/c  Radiation  +~: 
ASL 1  A/J  Spontaneous  + 
p80-negative tumors 
E2 (p 160  +)  B6  A-MuLV 
E3 (p160  +)  B6  A-MuLV 
B6T4(E) (p160  ÷)  B6  A-MuLV 
B6T6(E) (p160  +)  B6  A-MuLV 
EdG2  B6  Gross MuLV  +:~ 
Meth A  BALB/c  3-methylcholanthrene  -:~ 
BALENTL 9  BALB/c  Ethylnitrosourea  +§ 
RADA1  A/J  Radiation  +:~ 
AKSL2  AKR  Spontaneous  + 
K36  AKR  Spontaneous  -1: 
* Unless noted otherwise, the expression of the Thy- 1 antigen was determined in our 
laboratory in direct cytotoxicity tests with monoclonal anti-Thy-l.2 antibody. 
The expression of Thy-1, as reported in reference 20. 
§ The expression of Thy- 1, as reported in reference 2 i. 
marrow, lymph nodes, spleen, and thymus of B6, BALB/c, SWR, and DBA/2  mice 
were collected and labeled with  [aSS]methionine for incubation periods ranging from 
2-16  h.  In  no  instance  did  anti-pS0  antiserum  specifically  immunoprecipitate  a 
protein of 80,000 tool wt or one serologically related to it from lysates of any of these 
tissues. Under conditions in which the precipitating activity of anti-pS0 antiserum for 
the  radioactive p80  of B6TI(L)  cells was  limiting,  antiserum  was  incubated  with 
nonradioactive lysates of cells from  B6 lymph nodes, spleen, and thymus  before the 
addition of radioactive tumor cell lysates. The lymphoid extracts were generated from 
500-1,000 times the number of B6T I(L) ceils (2 ×  10  ~) used as a source of radioactive 
p80  in  these  competition  experiments.  The  amount  of  p80  precipitated  was  not 
measurably affected by preincubation of the antiserum with lymphoid extracts (data 
not shown). 
Two populations of rapidly dividing lymphoid cells were examined for synthesis of 
p80.  Regenerating  bone  marrow  cells  taken  10  d  after  reconstitution  of  lethally 
irradiated B6 mice did not synthesize p80  (data not shown).  Similarly, p80 was not 
detected in B6 spleen cells that were proliferating (16-fold stimulation of [aH]thymi- 
dine uptake)  in response to mitomycin C-treated BALB/c spleen cells (Fig. 8 A). 
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FIG.  7.  The 80,000-mol  wt proteins present in three different tumors are related. After immuno- 
precipitation and preparative gel electrophoresis, gel slices containing the p80 proteins from B6T 1  (L) 
cells, EL4 cells, and RLdl cells were cut out. The gel slices were mixed with 0.1 pg, 0.3/.tg,  or 1.0 
ttg S. aureus V8 protease, and the proteins were subjected to  partial enzymatic digestion during 
electrophoresis through a  15% SDS-polyacrylamide gel. 
TABLE  II 
Sera Tested  for the Ability to Precipitate  p8O  from B6TI (L) Cells 
Immunization*  Precipitation of pS0:~ 
B6 anti-B6Tl (E)  0/2§ 
B6 anti-B6Tl (L)  4/4 
(C3H ×  B6)Fa anti-B6Tl(L)  1/1 
B6 anti-A-MuLV  0/3 
B6 anti-B6Mo3  1/1 
BALB/c anti-EL4  1/1 
* 8-10-wk-old  mice were  injected subcutaneously with  10s-10 s  tumor cells. 
After these tumors had regressed,  10-fold increasing numbers of tumor cells 
were injected intraperitonealty every 2 wk until a dose of l0  s cells per mouse 
was reached. Thereafter, mice were immunized with  10  s cells.  B6 anti-A- 
MuLV  was  prepared  by  intravenous inoculation of mice with  104  focus- 
forming units of A-MuLV every 2 wk. With the exception of (C3H ×  B6)F1 
anti-B6T1 (L) antiserum, which was obtained from one mouse, each immu- 
nization reflects the pooled sera of 5-10 mice. 
:~ Data are expressed as the number of independent immunization experiments 
leading to the production of antibodies that precipitated pS0 per the total 
number of independent immunizations. 
§ These two antisera do, however, precipitate the A-MuLV gag-fusion proteins 
through recognition of non-M-MuLV antigenic determinants. 
in normal  tissues that would  have been detected by our procedures  (Fig. 8  B). Parallel 
cultures  of thymocytes  were  labeled  alone  or  after  mixing  with  varying  amounts  of 
p80-positive  FxlA  cells.  P80  and  p32  were  readily  visualized  in  immunoprecipitates 
from  tysates  of cultures  in  which  p80-positive  ceils  comprised  0.5%  of the  total  cell 
population  (Fig.  8  B,  lane  i).  However,  pS0  was  not  detected  in  normal  thymocytes 
that  had  been labeled  alone  (lanes f  and  g).  Only  one protein was  precipitated  from 1206  PS0:  A TUMOR-RELATED  PROTEIN  OF MOUSE  LYMPHOMAS 
FIG. 8.  Absence  of detectable p80 in normal lymphoid cells. (A) B6 spleen cells were cultured for 
4 d, either alone (lanes a and b) or in the presence of mitomycin C-treated BALB/c stimulator 
7  spleen cells (c and d).  10  viable spleen cells from each culture were metabolically labeled with 
[aSS]methionine,  lysed,  and analyzed, as in Material and Methods. Protein were immunoprecipitated 
with nonimmune mouse serum (a and c) or anti-p80 antiserum antiserum (b and d). Lane e is a 
parallel immunoprecipitation from B6TI(L) cells. (B) Parallel cultures of 108 thymocytes from B6 
mice were incubated  for  2.5  h  in  the  presence of 400 #Ci  [3SS]methionine.  Thymocytes were 
incubated either alone (fand g) or with 5 X 10  s (h), 2 X 108 (i), or 5 X 106 (j) FalA cells. Proteins 
were immunoprecipitated with nonimmune mouse serum (f) or anti-p80 antiserum (g-j) in the 
presence of M-MuLV virions. 
thymus extracts by anti-p80 antiserum but not nonimmune B6 serum. Reactivity for 
this  50,000  mol wt  species,  present  in B6Tl(L)  cells, has  been observed  in several 
pools of anti-p80 antisera. This result is analogous to that of others (15,  16) who also 
found that  p53,  a  common tumor antigen, was synthesized by normal thymocytes. 
Longer exposures of this fluorogram permit the conclusion that, if p80 were synthesized 
by normal B6 thymocytes, its synthetic rate in this population of cells would have to 
have been <0,05% that of its synthetic rate in the p80-positive tumor cells. 
Discussion 
Studies of Abelson lymphoma cells that  no longer expressed the A-MuLV trans- 
forming protein led to the identification of a  protein of ~80,000 tool wt that appears 
to be coordinately expressed with two minor species of 115,000 and 32,000 mol wt in 
many murine T  cell lymphomas. P80 is phosphorylated but not glycosylated in vivo 
and is not accessible to  lactoperoxidase iodination. Among A-MuLV-induced lym- 
phoma  cells, p80  has  been detected  only in those  tumors  and cell  lines that  have 
ceased synthesis of gag-fusion  proteins and have acquired a marker usually associated 
with T  lymphocyte differentiation. Several other molecular and phenotypic changes 
have been observed in these cells (J. Dudley, M. Scheid, C. Spellman, D. J, Grunwald, 
N. Warner, and R. Risser, unpublished observations), and these will be reported in 
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The association of p80  expression with  lymphomas of the T  lymphocyte lineage 
was borne out in the investigation of several murine tumors and cell lines. The 80,000- 
mol wt proteins synthesized by tumors induced by different agents and from different 
strains of mice were serologically and biochemically similar. However, not all Thy- 1- 
positive lymphomas synthesized  detectable  levels of pS0.  In  addition,  pS0 was  not 
detected in established fibroblastic cell lines, whether uninfected, infected with SFFV, 
or  transformed with  A-MuLV  or  SV40.  Thus,  synthesis  of pS0  is  not  a  universal 
feature of transformed murine or rat cells, but rather it is a common characteristic of 
murine T  cell lymphomas. 
The finding that syngeneic immunization with p80  + lymphomas frequently elicited 
the production of anti-pS0 antibodies suggests that this protein is either not expressed 
at all or only at very low levels in normal tissues. Competition experiments, designed 
to detect  molecules that might have low synthetic rates in normal tissues, failed to 
reveal proteins with pS0 antigenic determinants in B6 lymph node, thymus, or spleen 
tissue. In direct labeling experiments, we never observed immunoprecipitation of p80 
from extracts of normal B6, DBA/2, SWR, nor AKR lymphoid tissues. Reconstruction 
experiments indicated  that the level of synthesis of pS0 in a  population of adult B6 
thymocytes must be <0.05% that of tumor cells. 
PS0  appears to be unrelated  to  known  or endogenous  MuLV-encoded  proteins. 
Serological and biochemical analyses showed that pS0 is not related to the A-MuLV- 
specific gag-fusion proteins.  In  most  experiments,  p80  was  detected  in  immune 
reactions  performed  in  the  presence  of an  exogenous  source of MuLV,  such  that 
known MuLV determinants of the tumor ceils were successfully competed. Antisera 
directed against each of the internal structural proteins of Rauscher MuLV failed to 
immunoprecipitate pS0, and neither p80 nor p32 included the methionine-containing 
tryptic peptides of the major M-MuLV structural  protein, p30  (unpublished  obser- 
vations). 
Although  pS0  is  distinguishable  from  other  transformation-related  proteins,  it 
shares  some  features  with  the  A-MuLV-encoded gag-fusion protein  and  with  the 
recently  described  series  of tumor-associated  proteins  of ~53,000  mol  wt  (14-16). 
These three sets of proteins have similar physical properties, and all are unglycosylated 
immunogenic components of the cells in which they are found. Unlike the A-MuLV- 
specific protein,  the  presence  of pS0  does  not  correlate with  an  increased  cellular 
abundance of the amino acid phosphotyrosine. Although  E2 cells do have elevated 
levels of this unusual  amino acid, pl60-negative transplanted  A-MuLV cells do not 
(T. Hunter, personal communication). The 53K transformation-related proteins are 
synthesized in a wide variety of transformed and tumor cells, and these proteins can 
be readily detected in some normal tissue. The absence of pS0 from normal lymphoid 
cells and its detection in lymphoid tumors might indicate that pS0 is truly a  tumor- 
specific antigen, or, more likely, that pS0 is normally expressed in some other cell type 
and frequently activated in lymphoid tumors. 
Summary 
Examination of syngeneic tumor regressor sera prepared by immunization of mice 
with several different lymphomas revealed a common pattern of reactivity to proteins 
expressed  in  these  tumors.  Antibodies  present  in  these  sera  immunoprecipitate  a 
triplet of proteins of 115,000 mol wt (p115), 80,000 tool wt (p80), and 32,000 mol wt 1208  P80: A TUMOR-RELATED  PROTEIN  OF MOUSE  LYMPHOMAS 
(p32)  from  many  but  not  all  T  cell  lymphomas  of  mice.  P80,  the  predominant 
molecular species immunoprecipitated with these sera, is a nonglycosylated, phospho- 
protein that  does not  appear to be expressed at the cell surface.  Comparison  of the 
tryptic peptides of p32 and p80 indicated that the peptides found in p32 are a  subset 
of those found  in  p80.  Comparison  of the tryptic peptides of p80  with  those of the 
p120 gag-fusion  protein of Abelson murine leukemia virus demonstrated that pS0 and 
p120  did not share tryptic peptides. Comparison of the partial proteolytic products 
generated by treatment of pS0 molecules from different tumors with V8 protease did 
not  reveal  heterogeneity  in  p80  among  tumors  of different  strains  of mice.  Direct 
labeling and competition blocking experiments with lysates from normal cells failed 
to provide evidence of p80 synthesis in normal thymus, spleen, or bone marrow. Thus, 
p80 is a  biochemically identified tumor-related antigen of mouse lymphomas. 
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